Description

PA007513.m2a: Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1), Mouse IgG2a Kappa，In Vivo Grade

The in vivo grade recombinant anti-mouse VEGF mouse IgG2a kappa monoclonal antibody was produced in mammalian cells.

Citations of Syd Labs Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1):

1、Endothelial cell-derived IGFBP7 suppresses angiogenesis and tumor progression in colorectal cancer via the VAPA-TGF-β1 pathway
Peng Z, et al. J Exp Clin Cancer Res. 2026 Feb 16;45(1):73. doi: 10.1186/s13046-026-03664-z. PMID: 41692778; PMCID: PMC13011419.
“Mouse models：Igfbp7-Flox (NM-CKO-231807) …… At the end of the experiment, mice were euthanized, and colons were collected for macroscopic tumor counting, histological evaluation, and molecular analyses. The murine anti-VEGF monoclonal antibody (Syd Labs, clone: B20-4.1.1.1) and the isotype control mouse IgG2a kappa antibody (Syd Labs, clone: 12B9) were administered via intraperitoneal injection at a dose of 5 mg/kg, twice per week.”

“IGFBP7 inhibits tumor growth and angiogenesis in mouse models …… Q Schematic diagram illustrating the experimental design in the AOM/DSS-induced colitis-associated colorectal cancer model. Mice were administered intraperitoneal injections of saline (100 µl/mouse) or recombinant IGFBP7 protein (10 µg/mouse) once per week, as well as mouse IgG2a Kappa antibody (5 mg/kg) or the anti-VEGF monoclonal antibody B20-4.1.1.1 (5 mg/kg) twice per week. Created with BioRender.com …… ”

“Subsequently, to evaluate whether IGFBP7 could enhance the anti-angiogenic therapeutic efficacy of bevacizumab, we co-administered the murine anti-VEGF antibody B20-4.1.1.1 together with recombinant mouse IGFBP7 (rmIGFBP7) and assessed their anti-tumor effects in the AOM/DSS mouse model …… indicating that IGFBP7 enhances the anti-tumor efficacy of anti-VEGF therapy.”

References For Anti-mouse VEGF Monoclonal Antibody:

1、Endothelial F3-mediated autolysosome and lipid metabolism promote resistance to anti-VEGFA therapy in metastatic colorectal cancer
Nan Huang et al. Autophagy 2025 Dec;21(12):3004-3023. doi: 10.1080/15548627.2025.2551720. Epub 2025 Sep 8. PMID: 40922383
“Patients with metastatic colorectal cancer (mCRC) to the liver exhibit poor survival rates. Chemotherapy combined with anti-vascular therapy has emerged as the standard treatment, but resistance to anti-VEGFA therapy inevitably develops. The metabolic reprogramming of tumor vascular endothelial cells (TECs) plays a crucial, yet still poorly understood, role in the development of therapeutic resistance. We identified lipid-rich and fatty acid oxidation (FAO)-activated proliferating TECs in fatty colorectal cancer liver metastasis (CRLM) that mediate resistance to anti-VEGFA treatment. The TEC-specific F3 protein inhibited the macroautophagy/autophagy-lysosome pathway through the MAPK/JNK-MAPK/ERK-TP53/p53 signaling axis, thereby prevented CPT1A protein degradation and enhanced FAO. F3 was also involved in promoting lipid uptake and lipophagy. This process promoted cellular FAO under conditions of fatty acids and anti-VEGFA stimulation. Targeting FAO proved effective in overcoming resistance to anti-VEGFA treatment. Our findings elucidated the role of lipid metabolism in therapy-resistant TECs in fatty CRLM and provided a theoretical foundation for further research on anti-VEGFA therapy resistance. Moreover, we underscored the potential of combining FAO inhibitors to enhance the efficacy of anti-angiogenic therapy.”
Tags: anti-mouse VEGF antibody; anti-mouse VEGF antibody for cancer research

2、Radiosensitizing oxygenation changes in murine tumors treated with VEGF-ablation therapy are measurable using oxygen enhanced-MRI (OE-MRI)
Jennifer Hazel Elizabeth Baker, Andrew I Minchinton et al. Radiother Oncol. 2023. PMID: 37414252
“Murine squamous cell carcinoma (SCCVII) tumor-bearing mice were treated with 5 mg/kg anti-VEGF murine antibody B20 (B20-4.1.1, Genentech) 2-7 days prior to radiation treatment, tissue collection or MR imaging using a 7 T scanner. dOE-MRI scans were acquired for a total of three repeated cycles of air (2 min) and 100% oxygen (2 min) with responding voxels indicating tissue oxygenation. DCE-MRI scans were acquired using a high molecular weight (MW) contrast agent (Gd-DOTA based hyperbranched polygylcerol; HPG-GdF, 500 kDa) to obtain fractional plasma volume (fPV) and apparent permeability-surface area product (aPS) parameters derived from the MR concentration-time curves. Changes to the tumor microenvironment were evaluated histologically, with cryosections stained and imaged for hypoxia, DNA damage, vasculature and perfusion. Radiosensitizing effects of B20-mediated increases in oxygenation were evaluated by clonogenic survival assays and by staining for DNA damage marker γH2AX.”
Tags: anti-mouse VEGF antibody; anti-mouse VEGF antibody for cancer research

3、Modulation of vascular response after injury in the rat Achilles tendon alters healing capacity
Corinne N Riggin, Benjamin R Freedman, Meghna S Murthy et al. J Orthop Res. 2021. PMID: 32936495
“Fischer rats received a bilateral Achilles incisional injury followed by local injections of vascular endothelial growth factor (VEGF), anti-VEGF antibody (B20.4-1-1), or saline either early or late during the healing process. Vascular modulation and healing were evaluated using multiple in vivo ultrasound imaging modalities, in vivo functional assessment, and ex vivo measures of tendon compositional and mechanical properties. The late delivery of anti-VEGF antibody, B20, caused a temporary reduction in healing capacity during a time point where vascularity was also decreased, and then an improvement during a later time point where vascularity was increased relative to control. However, VEGF delivery had a minimal impact on healing and vascular changes in both early and late delivery times. This study was the first to evaluate vascular changes using both in vivo imaging methods and ex vivo histological methods, as well as functional and mechanical outcomes associated with these vascular changes. Clinical significance: this study demonstrates that the alteration of vascular response through the delivery of angiogenic growth factors has the ability to alter tendon healing properties.”
Tags: anti-mouse VEGF B20-4.1.1 mAb in animal model; anti-mouse VEGF B20-4.1.1 in cancer research

4、TNFα secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy
Qingxia Wei, Ivana Zubiaurre Martinez et al. Acta Neuropathol Commun. 2021. PMID: 33853689
“We further demonstrated in mouse model that treatment with B20.4.1.1, the mouse analog of Bevacizumab, increased macrophage recruitment to the tumor area and correlated with upregulated TNFalpha expression in GAMs and increased EC activation, which may be res …”
Tags: bioactivity of anti-mouse VEGF B20-4.1; anti-mouse VEGF B20-4.1 of low endotoxin

Related Recombinant IgG Reference Antibodies:
Recombinant mouse IgG2a isotype control antibody, In vivo grade

Syd Labs provides the following in vivo grade recombinant anti-mouse VEGF monoclonal antibodies:
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1), In vivo grade
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-23), In vivo grade
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31), In vivo grade
Recombinant anti-mouse VEGF / PD-1 bispecific antibodies (Clone B20-4.1.1.1 / RMP1-14.1), In vivo grade
Recombinant anti-mouse VEGF / PD-1 bispecific antibodies (Clone B20-4.1.1.1 / 29F.1A12.1), In vivo grade
Recombinant anti-mouse VEGF / PD-L1 bispecific antibodies (Clone B20-4.1.1.1 / 10F.9G2.1), In vivo grade
Recombinant anti-mouse VEGF / PD-1 bispecific antibodies (Clone G6-23 / RMP1-14.1), In vivo grade
Recombinant anti-mouse VEGF / PD-1 bispecific antibodies (Clone G6-23 / 29F.1A12.1), In vivo grade
Recombinant anti-mouse VEGF / PD-L1 bispecific antibodies (Clone G6-23 / 10F.9G2.1), In vivo grade
Recombinant anti-mouse VEGF / PD-1 bispecific antibodies (Clone G6-31 / RMP1-14.1), In vivo grade
Recombinant anti-mouse VEGF / PD-1 bispecific antibodies (Clone G6-31 / 29F.1A12.1), In vivo grade
Recombinant anti-mouse VEGF / PD-L1 bispecific antibodies (Clone G6-31 / 10F.9G2.1), In vivo grade

Syd Labs provides the following recombinant anti-mouse VEGF monoclonal antibodies for Flow Cytometry:
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-23) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31) for Flow Cytometry

Syd Labs also provides the following anti-VEGF antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc silent mutant
Ramucirumab Biosimilar, research grade, anti-human VEGF / VEGFR2 / VEGFR-2 monoclonal antibody
Ranibizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Brolucizumab Biosimilar, research grade, VEGF-A Monoclonal Antibody
Faricimab Biosimilar, research grade, Human ANGPT2/VEGFA Monoclonal Antibody

Anti-mouse VEGF Antibody (B20-4.1.1.1) from: In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1), Mouse IgG2a Kappa: PA007513.m2a Syd Labs